Insmed Incorporated, a global biopharmaceutical company, has announced the granting of inducement awards to 150 new employees under its 2025 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards, approved by Insmed's Compensation Committee, include 155,822 restricted stock units and options to purchase 16,860 shares of Insmed common stock at an exercise price of $69.73 per share. The restricted stock units will vest over a four-year period, with 25% of the shares vesting annually, contingent upon continued employment with Insmed. This initiative underscores Insmed's commitment to attracting top talent in the biopharmaceutical industry.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。